David Bower

Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: A case study using aromatic amine mutagenicity

Ernst Ahlberg, Alexander Amberg, Lisa Beilke et al. · Regulatory Toxicology and Pharmacology · 2016 · 47 citations

Pharmacy, Toxicology, Pharmaceutical Toxicology +7

Skin sensitization in silico protocol

Candice Johnson, Ernst Ahlberg, Lennart T. Anger et al. · Regulatory Toxicology and Pharmacology · 2020 · 47 citations · Full text

Pharmacy, Dermatology, Toxicology +14

The ToxBank Data Warehouse: Supporting the Replacement of In Vivo Repeated Dose Systemic Toxicity Testing

Pekka Kohonen, Emilio Benfenati, David Bower et al. · Molecular Informatics · 2013 · 43 citations · Full text

Pharmacy, Toxicology, Molecular Toxicology +15

Evaluating confidence in toxicity assessments based on experimental data and in silico predictions

Candice Johnson, Lennart T. Anger, Romualdo Benigni et al. · Computational Toxicology · 2021 · 25 citations · Full text

Pharmacy, Toxicology, Toxicodynamics +12

Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: is aromatic<i>N</i>-oxide a structural alert for predicting DNA-reactive mutagenicity?*

Alexander Amberg, Lennart T. Anger, Joel P. Bercu et al. · Mutagenesis · 2018 · 17 citations · Full text

Pharmacy, Toxicology, Analytical Toxicology +16